EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Immune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023

Kristoffer Illergard iD, Pablo Soto iD, Johannes Arpegård iD, Aglaia Schiza iD, Simon Pahnke iD

Upsala Journal of Medical Sciences · 12.08.2026 · 131 · 14245

DOI: 10.48101/ujms.v131.14245 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Upsala Journal of Medical Sciences, online erschienen am 12.08.2026. Verfasst von Kristoffer Illergard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Informatics & Visualization, Reveal AB, Stockholm, Sweden. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of immune checkpoint inhibitor (ICI) treatment has significantly improved the treatment of several cancer diagnoses, such as non-small cell lung cancer, renal and urothelial carcinoma, melanoma. However, there is a lack of real-world data on ICI treatment and outcomes from the Swedish healthcare setting. The cost of treatment is also significant, and securing equal access to emerging drugs for all patients is challenging in an era of rapidly evolving treatment recommendations.

Methods

We conducted a population-based observational study of incident cases among ICI-treated patients, using a novel electronic healthcare record source for systemic cancer drugs linked to regional and national register data. Overall survival (OS) was calculated from start of the first ICI-treatment, using the Kaplan-Meier method. The aim was to examine treatment with ICI drugs during 2015–2023 in 10 Swedish regions (total population 4.3 million).

Results

Median real-world OS was 2.0 years (95% confidence interval: 1.8–2.2 years) from start of ICI-treatment for patients with known palliative treatment intent (n = 1,941, lung 2.2 years, melanoma 5.0 years, renal 2.3 years, urothelial 1.1 years, head/neck 1.4 years). In 2023, 6.7% of all patients receiving systemic antineoplastic treatment for cancer were treated with ICI (74 per 100,000 inhabitants). The timing of the adoption of treatment with ICI drugs and the current patterns of use differed between Swedish regions.

Conclusion

This study provides the first Swedish real-world OS estimates after ICI-treatment across major diagnoses, documents the rapidly increasing ICI use, and describes regional variation in treatment patterns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansSwedenFemaleMaleAgedTreatment OutcomeMiddle AgedKaplan-Meier EstimateAged, 80 and overRegistriesLung Neoplasms

Stichwörter der Autor:innen

Immune checkpoint inhibitorscancer treatmentreal-world outcomes

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Research, Informatics & Visualization, Reveal AB, Stockholm, Sweden.
  • Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Kristoffer Illergard, Pablo Soto, Johannes Arpegård, Aglaia Schiza, Simon Pahnke

Zitieren

APA

Illergard, K., Soto, P., Arpegård, J., Schiza, A., & Pahnke, S. (2026). Immune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023. Upsala Journal of Medical Sciences, 131, 14245. https://doi.org/10.48101/ujms.v131.14245

Vancouver

Illergard K, Soto P, Arpegård J, Schiza A, Pahnke S. Immune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023. Upsala Journal of Medical Sciences. 2026;131:14245. doi:10.48101/ujms.v131.14245

BibTeX
@article{Illergard2026,
  author = {Illergard, Kristoffer and Soto, Pablo and Arpegård, Johannes and Schiza, Aglaia and Pahnke, Simon},
  title = {Immune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023},
  journal = {Upsala Journal of Medical Sciences},
  year = {2026},
  volume = {131},
  pages = {14245},
  doi = {10.48101/ujms.v131.14245}
}
Kostenlos starten →